Viking Therapeutics, Inc. (VKTX)
| Market Cap | 3.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -359.64M |
| Shares Out | 115.89M |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,837,695 |
| Open | 33.20 |
| Previous Close | 32.99 |
| Day's Range | 32.36 - 33.86 |
| 52-Week Range | 22.96 - 43.15 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 94.44 (+191.57%) |
| Earnings Date | Apr 29, 2026 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $94.44, which is an increase of 191.57% from the latest price.
News
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharm...
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage bi...
Viking Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Phase III trials for dual agonist VK2735 are progressing rapidly, with key data readouts and a maintenance study expected in Q3 2026. The company is leveraging a differentiated product profile, efficient trial design, and a flexible commercial strategy to compete in a segmented obesity market.
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra...
Viking Therapeutics plans to advance oral obesity drug to late-stage trial
Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Viking Therapeutics Stock Climbs After Q4 Report: Details
Viking Therapeutics, Inc. (NASDAQ:VKTX) shares climbed in Wednesday's extended trading after the company released its fourth-quarter earnings report.
Viking Therapeutics Earnings Call Transcript: Q4 2025
Multiple clinical milestones achieved in 2025, including advancing both subcutaneous and oral VK2735 into late-stage trials, with strong efficacy and safety data. Net loss increased due to higher R&D spend, but cash reserves remain strong to fund upcoming Phase III trials and new programs.
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Compl...
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmac...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Appetite for weight-loss deals broader than visible, Viking CEO says
Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers seek to tap into the potential $150 billio...
Viking Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Lead dual agonist VK2735 is advancing in both oral and sub-Q forms, showing strong, durable weight loss and good tolerability in phase II studies. Phase III VANQUISH trials are underway, with data expected in 2027, and maintenance dosing strategies are a focus. Strategic and licensing interest in the pipeline remains high.
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program ...
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNews...
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a ...
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...
Viking Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Lead obesity drug VK2735, in both oral and subQ forms, showed strong, dose-dependent weight loss and good tolerability in phase II trials. Phase III studies are underway, with key data and regulatory meetings expected over the next year.
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO , Nov. 19, 2025 /PRNews...
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeu...
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Stanley Druckenmiller 's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionair...
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific S...